Exelixis (EXEL) Income towards Parent Company (2010 - 2026)
Exelixis (EXEL) recorded quarterly Income towards Parent Company of $210.5 million in Q2 2026, down 13.93% quarter-over-quarter from $244.5 million in Q1 2026, and up 31.86% on a YoY basis from $159.6 million in Q2 2025.
Exelixis (EXEL) Income towards Parent Company (2010 - 2026) Analysis & Trends
Exelixis' Income towards Parent Company history runs 17 years deep, the most recent figure standing at $210.5 million for Q2 2026.
- In Q2 2026, Income towards Parent Company rose 31.86% year-over-year to $210.5 million; the TTM figure through Apr 2026 stood at $833.4 million (up 29.5% YoY), while the FY2026 annual figure was $782.6 million, up 50.13% from the prior year.
- Income towards Parent Company was $210.5 million for Q2 2026 at Exelixis, down from $244.5 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $244.5 million in Q1 2026 to a low of -$30.2 million in Q4 2022.
- Historically, Income towards Parent Company has averaged $112.0 million across 5 years, with a median of $85.5 million in 2023.
- The sharpest annual moves came in 2022 and 2024: Income towards Parent Company plunged 131.71% in 2022, then jumped 11232.66% in 2024.
- A 5-year view of Income towards Parent Company shows it stood at -$30.2 million in 2022, then surged by 383.43% to $85.5 million in 2023, then jumped by 37.95% to $118.0 million in 2024, then jumped by 64.09% to $193.6 million in 2025, then increased by 8.72% to $210.5 million in 2026.
- The last three Income towards Parent Company figures came in at $210.5 million (Q2 2026), $244.5 million (Q1 2026), and $193.6 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Exelixis | 13.61 Bn | 12.83 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 210.47 Mn |
| Jan 2, 2026 | 244.53 Mn |
| Oct 3, 2025 | 193.58 Mn |
| Jul 4, 2025 | 184.85 Mn |
| Apr 4, 2025 | 159.62 Mn |
| Jan 3, 2025 | 139.86 Mn |
| Sep 27, 2024 | 117.97 Mn |
| Jun 28, 2024 | 226.12 Mn |
| Mar 29, 2024 | 37.32 Mn |
| Dec 29, 2023 | 85.52 Mn |
| Sep 29, 2023 | 1.04 Mn |
| Jun 30, 2023 | 81.18 Mn |
| Mar 31, 2023 | 40.03 Mn |
| Dec 30, 2022 | -30.17 Mn |
| Sep 30, 2022 | 73.21 Mn |
| Jul 1, 2022 | 70.67 Mn |
| Apr 1, 2022 | 68.57 Mn |
| Dec 31, 2021 | 95.17 Mn |
| Oct 1, 2021 | 38.20 Mn |
| Jul 2, 2021 | 96.09 Mn |